title: Suppressive effect on Theiler's murine encephalomyelitis virus-induced demyelinating disease by the administration of anti-IL-12 antibody.
abstract: We examined the role of IL-12, a cytokine critical to the evolution of cellular responses, in the development of Theiler's murine encephalomyelitis virus-induced demyelinating disease (TMEV-IDD). Treatment with mAbs to IL-12, especially during the effector phase, resulted in significant suppression of the development of this disease both clinically and histologically. In mice treated with these mAbs, the production of inflammatory and Th1-derived cytokines such as TNF-alpha and IFN-gamma in the spleen cells was decreased, and that of Th2-derived cytokines such as IL-4 and IL-10 was increased. The delayed type hypersensitivity and T cell proliferative response specific for TMEV were decreased by this treatment. These data suggest that IL-12 is critically involved in the pathogenesis of TMEV-IDD and that Abs to IL-12 could be a novel therapeutic approach in the clinical treatment of demyelinating diseases such as human multiple sclerosis.
authors.affiliation: Third Department of Medicine, Shinshu University School of Medicine, Matsumoto, Japan.
authors.forename: A
authors.initials: A
authors.lastname: Inoue
authors.forename: C S
authors.initials: CS
authors.lastname: Koh
authors.forename: M
authors.initials: M
authors.lastname: Yamazaki
authors.forename: H
authors.initials: H
authors.lastname: Yahikozawa
authors.forename: M
authors.initials: M
authors.lastname: Ichikawa
authors.forename: H
authors.initials: H
authors.lastname: Yagita
authors.forename: B S
authors.initials: BS
authors.lastname: Kim
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D000914:Antibodies, Viral / Q000096:biosynthesis; D000918:Antibody Specificity; D018188:Cardiovirus Infections / Q000276:immunology* / Q000517:prevention & control / Q000821:virology; D006224:Cricetinae; D016207:Cytokines / Q000096:biosynthesis; D003711:Demyelinating Diseases / Q000276:immunology* / Q000517:prevention & control / Q000821:virology; D004198:Disease Susceptibility; D005260:Female; D006968:Hypersensitivity, Delayed / Q000276:immunology / Q000821:virology; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007276:Injections, Intraventricular; D018664:Interleukin-12 / Q000276:immunology*; D008213:Lymphocyte Activation / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D008815:Mice, Inbred Strains; D008819:Mice, Nude; D013601:T-Lymphocytes / Q000276:immunology / Q000821:virology; D017945:Theilovirus / Q000276:immunology* / Q000472:pathogenicity
chemical_list: D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral; D016207:Cytokines; D007166:Immunosuppressive Agents; D018664:Interleukin-12